NIH grants $9m for nicotine cessation drug development
The US National Institutes of Health (NIH) unit National Institute on Drug Abuse (NIDA) has granted an award of $9m for researchers to advance drug, SBP-9330, to treat nicotine addiction.
The US National Institutes of Health (NIH) unit National Institute on Drug Abuse (NIDA) has granted an award of $9m for researchers to advance drug, SBP-9330, to treat nicotine addiction.
Oricell Therapeutics has announced the clearance of its Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for OriCAR-017, a new CAR-T cell therapy targeting GPRC5D, for the treatment of relapsed/refractory multiple myeloma (R/R MM).
The Progeria Research Foundation (PRF) has announced the Japanese approval of Zokinvy (lonafarnib) for treating Progeria and processing-deficient Progeroid Laminopathies (PL).
Chinese biotechnology company GenFleet Therapeutics has received the US Food and Drug Administration (FDA) designations for its drug candidate SLS009 (GFH009).
AGC Biologics has announced the establishment of a new manufacturing site at the AGC Yokohama Technical Center in Japan.
Innovent Biologics has signed a partnership agreement with Sanegene Bio to jointly develop an angiotensinogen (AGT) directed siRNA drug candidate, SGB-3908, to treat hypertension.
LimmaTech Biologics and AbVacc have entered into a licensing agreement, under which the former will get exclusive rights for the continued development of the latter's multivalent toxoid vaccine candidate, LBT-SA7 (previously known as IBT-V02).
Aldevron, a US-based developer and manufacturer of plasmid DNA, RNA and proteins for the biotech industry, has signed an agreement with US-based enzyme engineering company Codexis to acquire global exclusive license to Codex HiCap RNA Polymerase.
Pharmaceutical company focused on medical dermatology Almirall has signed a multi-target alliance with mRNA/LNP technology platform company etherna to discover and develop new mRNA-based therapies to address severe skin diseases, including non-melanoma skin cancer.
Rigel Pharmaceuticals has entered into a multi-year strategic development collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) for expanding the assessment of REZLIDHIA (olutasidenib) in acute myeloid leukaemia (AML) and other haematologic cancers.